54 articles with Aptinyx
Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced that David R. Houck, Ph.D. has been promoted to chief development officer.
Aptinyx Presents Data on NMDA Receptor Modulator NYX-458 in a Preclinical Model of Parkinson's Cognitive Impairment at the AAT-AD/PD Focus Meeting 2018
Aptinyx Inc. announced the presentation of preclinical data that supports advancing the development of a novel N-methyl D-aspartate (NMDA) receptor modulator, NYX-458, as a treatment for cognitive impairment associated with Parkinson's disease.
Aptinyx Presents Preclinical and Phase 1 Clinical Data from NYX-2925 at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics
Aptinyx Inc. announced they will present preclinical and early-stage clinical data from studies of the company's lead product candidate, NYX-2925, at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics, March 7-10, 2018 in Rockville, MD.
Aptinyx Presents NYX-2925 Preclinical Data in Chemotherapy-induced Neuropathic Pain at the American Pain Society Annual Scientific Meeting
Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced their presentation at the American Pain Society's Annual Scientific Meeting, March 4-6, 2018 in Anaheim, CA.
Mr. Khanna has served as chief business officer of Aptinyx since the company's inception in 2015.
The round was led by Bain Capital Life Sciences.
Aptinyx Granted Fast Track Designation, Initiates Phase I for Second Clinical Candidate, NYX-783, in Post-Traumatic Stress Disorder
The U.S. Food and Drug Administration has granted Aptinyx Fast Track designation for the development of NYX-783 for the treatment of PTSD.
Andy's experience will be instrumental in achieving and leveraging anticipated milestones,.
Aptinyx Chief Scientific Officer Joseph Moskal, Ph.D. Named Fellow By National Academy Of Inventors And The American Institute For Medical And Biological Engineering
Aptinyx Awarded Up To $2.85 Million In NIH Grants To Research NMDA Receptor Modulation For The Treatment Of Neuropathic Pain And Age-Related Cognitive Decline
Aptinyx Receives FDA Fast Track Designation For Development Of NYX-2925 As Treatment For Neuropathic Pain Associated With Diabetic Peripheral Neuropathy